Amryt Pharma granted another two US patents

Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate ‘Oleogel-S10’ on Tuesday, as well as its recently-acquired and third commercial product ‘Mycapssa’.

The AIM-traded firm said the United States Patent and Trademark Office (USPTO) has issued a new US formulation patent for Oleogel-S10, titled ‘Betulin-Containing Birch Bark Extracts and their Formulation’.

It said that if Oleogel-S10 was approved by the US Food and Drug Administration (FDA), the patent would be listable in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the ‘Orange Book’, published by the FDA.

The patent would expire in January 2039.

Together with three previously-granted patents, if Oleogel-S10 was approved, Amryt said it would have four Orange Book-listed patents for Oleogel-S10, with patent protection through January 2039, without patent term extension.

The company said the USPTO also issued a new US patent related to the Mycapssa, granting claims covering “methods of administering oral octreotide with certain oral contraceptives”.

It said the patent would expire in December 2040, and would also be listable in the Orange Book.

Amryt said it now had eight Orange Book-listed patents for Mycapssa, with patent protection through December 2040.

“We are always working to develop and extend our intellectual property portfolio, and today’s news further illustrates the robust IP protection enjoyed by both our commercial and development assets,” said chief executive officer Joe Wiley.

At 1444 BST, shares in Amryt Pharma were flat at 177p.